Evidence map›Paper›PMID 40612504›Full record

ArticleiScience2025

Functional impact of the hyperduplication genomophenotype in high copy number endometrial cancer.

Angela Florio, James Smadbeck, Sarah H Johnson, Wan-Hsin Lin, Dorsay Sadeghian, Sotiris Sotiriou, Rebeca Salvatori, Ryan W Feathers, Taylor Berry, Lindsey Kinsella and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Angela FlorioBiomarker Discovery Laboratory, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
James SmadbeckDivision of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Sarah H JohnsonBiomarker Discovery Laboratory, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
Wan-Hsin LinDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.
Dorsay SadeghianDepartment of Lab Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Sotiris SotiriouDepartment of Lab Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Rebeca SalvatoriDepartment of Lab Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Ryan W FeathersDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.
Taylor BerryDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.
Lindsey KinsellaDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.
Faye R HarrisBiomarker Discovery Laboratory, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
Alexa F McCuneBiomarker Discovery Laboratory, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
Stephen J MurphyBiomarker Discovery Laboratory, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
Mohamed F AliBiomarker Discovery Laboratory, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
Abdulmohammad PezeshkiBiomarker Discovery Laboratory, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
Michael T BarrettDivision of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA.
Leah GrcevichDepartment of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA.
Ilaria CapassoDepartment of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA.
Luigi Antonio De VitisDepartment of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA.
Gabriella SchivardiDepartment of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA.
Tommaso OcchialiDepartment of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA.
Alyssa M LarishDepartment of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA.
John WerohaDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Mitesh J BoradDivision of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA.
John ChevilleDepartment of Lab Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Panos Z AnastasiadisDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.
Andrea MarianiDepartment of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA.
George VasmatzisBiomarker Discovery Laboratory, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High copy-number endometrial cancers (HCNECs) are dominated by excessive duplications scattered across the genome, termed here as the hyperduplication genomophenotype (HDGP). We identified locations and sizes of duplications in 171 endometrial cancer cases and designated 71 HCNEC cases as HDGP. We also investigated the response to the pan-ERBB inhibitor afatinib in a subset of HDGP-EC cases with

Indexed as

BioinformaticsBiological sciencesCancerGenomics

Identifiers

PMID40612504
PMCPMC12221648

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.